Appeals court reverses Novartis win over Regeneron in Eylea-Lucentis battle
Regeneron on Monday successfully flipped a lower court’s decision in a hotly-contested case against Novartis regarding the companies’ competing eye injections.
The US Court of Appeals for the Second Circuit in Manhattan backed Regeneron after the company argued that a district court improperly dismissed its antitrust claims, among other arguments. The suit, which dates back to July 2020, relates to competition between Regeneron’s blockbuster Eylea and Novartis’ Lucentis, both of which are anti-VEGF treatments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
